Kai Li

3.4k total citations
95 papers, 1.8k citations indexed

About

Kai Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kai Li has authored 95 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 27 papers in Molecular Biology. Recurrent topics in Kai Li's work include Lung Cancer Research Studies (37 papers), Lung Cancer Treatments and Mutations (26 papers) and Lung Cancer Diagnosis and Treatment (20 papers). Kai Li is often cited by papers focused on Lung Cancer Research Studies (37 papers), Lung Cancer Treatments and Mutations (26 papers) and Lung Cancer Diagnosis and Treatment (20 papers). Kai Li collaborates with scholars based in China, United States and Australia. Kai Li's co-authors include Zhujun Liu, Richeng Jiang, Tingting Qin, Yanan Jia, Baohui Han, Shaochuan Liu, Ying Cheng, Xinyue Wang, Zhehai Wang and Jianhua Shi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Kai Li

90 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kai Li China 23 1.2k 675 477 341 242 95 1.8k
Giulia Pasello Italy 23 1.1k 0.9× 1.1k 1.6× 510 1.1× 349 1.0× 207 0.9× 165 2.0k
Puyuan Xing China 22 1.2k 1.0× 1.0k 1.5× 461 1.0× 295 0.9× 151 0.6× 149 1.7k
Motoko Tachihara Japan 21 1.1k 1.0× 1.2k 1.8× 443 0.9× 249 0.7× 288 1.2× 109 1.9k
Tommaso Martino De Pas Italy 19 950 0.8× 943 1.4× 307 0.6× 268 0.8× 233 1.0× 45 1.5k
Xue Hou China 26 1.3k 1.1× 1.0k 1.5× 376 0.8× 317 0.9× 212 0.9× 104 2.1k
Francesco Facchinetti Italy 25 1.1k 1.0× 1.2k 1.8× 827 1.7× 386 1.1× 161 0.7× 79 2.1k
Atsushi Horiike Japan 28 1.3k 1.1× 1.3k 2.0× 604 1.3× 391 1.1× 146 0.6× 107 2.1k
Carmen Belli Italy 20 1.0k 0.9× 517 0.8× 550 1.2× 401 1.2× 116 0.5× 60 1.7k
Leila Khoja United Kingdom 20 1.7k 1.4× 612 0.9× 416 0.9× 388 1.1× 155 0.6× 50 2.1k
Pallavi S. Mishra‐Kalyani United States 22 883 0.8× 560 0.8× 332 0.7× 191 0.6× 121 0.5× 49 1.5k

Countries citing papers authored by Kai Li

Since Specialization
Citations

This map shows the geographic impact of Kai Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Li more than expected).

Fields of papers citing papers by Kai Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Li. The network helps show where Kai Li may publish in the future.

Co-authorship network of co-authors of Kai Li

This figure shows the co-authorship network connecting the top 25 collaborators of Kai Li. A scholar is included among the top collaborators of Kai Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai Li. Kai Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Tong, et al.. (2025). N6-methyladenosine-modified circQKI inhibits prostate cancer docetaxel-sensitivity via miR-188-3p/Beclin-1 pathway. Life Sciences. 372. 123646–123646. 2 indexed citations
2.
3.
Wu, Yalan, Huixia Liu, Kai Li, et al.. (2024). The adhesion-GPCR ADGRF5 fuels breast cancer progression by suppressing the MMP8-mediated antitumorigenic effects. Cell Death and Disease. 15(6). 455–455. 8 indexed citations
4.
5.
6.
7.
Liao, Ning, Cheukfai Li, Li Cao, et al.. (2022). Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node. Breast Cancer. 30(1). 77–87. 3 indexed citations
8.
Liu, Ying, Ying Cheng, Qiming Wang, et al.. (2021). Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study. Thoracic Cancer. 12(22). 3039–3045. 8 indexed citations
9.
Cheng, Ying, Qiming Wang, Kai Li, et al.. (2021). Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial. Cancer Medicine. 11(4). 1081–1087. 15 indexed citations
10.
Cheng, Ying, Qiming Wang, Kai Li, et al.. (2021). Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study. British Journal of Cancer. 125(3). 366–371. 103 indexed citations
11.
Zhang, Cuicui, Jing Wang, Xinyue Wang, et al.. (2021). Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer. Cancer Biology and Medicine. 19(8). 1249–1258. 4 indexed citations
12.
Chu, Tianqing, Jun Lü, Minghong Bi, et al.. (2021). Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer Biology and Medicine. 18(3). 816–824. 23 indexed citations
13.
14.
Qin, Tingting, Zhujun Liu, Jing Wang, et al.. (2020). Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling. Cancer Biology and Medicine. 17(3). 753–767. 32 indexed citations
15.
Zhao, Yuhang, Xinghuan Wang, Hong Weng, et al.. (2018). The Clinical Significance of O6-Methylguanine-DNA Methyltransferase Promoter Methylation Status in Adult Patients With Glioblastoma: A Meta-analysis. Frontiers in Neurology. 9. 127–127. 36 indexed citations
16.
Liu, Yi, et al.. (2017). Risk factors of colorectal cancer and its clinical epidemiological study. Biomedical Research-tokyo. 28(22). 9871–9874. 2 indexed citations
17.
Cao, Qinchen, Lujun Zhao, Changli Wang, et al.. (2015). Reappraisal of the role of postoperative radiation therapy in patients with pIIIa‐N2 non‐small cell lung cancer: A propensity score matching analysis. Thoracic Cancer. 6(5). 570–578. 4 indexed citations
18.
Wang, Xinyue, Richeng Jiang, & Kai Li. (2014). Prognostic Significance of Pretreatment Laboratory Parameters in Combined Small-Cell Lung Cancer. Cell Biochemistry and Biophysics. 69(3). 633–640. 45 indexed citations
19.
Jiang, Xiangli, et al.. (2014). Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes. Tumor Biology. 36(2). 861–869. 7 indexed citations
20.
Li, Kai. (2007). A randomized comparative trial of NVB alone versus NVB plus DDP for treatment of elderly patients with non-small cell lung cancer. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giulia Pasello Breakdown of academic impact, for papers by Puyuan Xing Breakdown of academic impact, for papers by Motoko Tachihara Breakdown of academic impact, for papers by Tommaso Martino De Pas Breakdown of academic impact, for papers by Xue Hou Breakdown of academic impact, for papers by Francesco Facchinetti Breakdown of academic impact, for papers by Atsushi Horiike Breakdown of academic impact, for papers by Carmen Belli Breakdown of academic impact, for papers by Leila Khoja Breakdown of academic impact, for papers by Pallavi S. Mishra‐Kalyani
Rankless by CCL
2026